Find information on thousands of medical conditions and prescription drugs.

Itraconazole


Itraconazole (marketed as Sporanox® by Janssen Pharmaceutica) is an antifungal agent that is prescribed to patients with fungal infections. The drug may be given orally or intravenously. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
Ibuprofen
Idarubicin
Idebenone
IFEX
Iloprost
Imatinib mesylate
Imdur
Imipenem
Imipramine
Imiquimod
Imitrex
Imodium
Indahexal
Indapamide
Inderal
Indocin
Indometacin
Infliximab
INH
Inosine
Intal
Interferon gamma
Intralipid
Invanz
Invirase
Iontocaine
Iotrolan
Ipratropium bromide
Iproniazid
Irbesartan
Iressa
Irinotecan
Isocarboxazid
Isoflurane
Isohexal
Isoleucine
Isomonit
Isoniazid
Isoprenaline
Isordil
Isosorbide
Isosorbide dinitrate
Isosorbide mononitrate
Isotretinoin
Itraconazole
Ivermectin
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Pharmacology

The mechanism of action of itraconazole is the same as the other azole antifungals: it inhibits cytochrome P450 oxidase mediated sysnthesis of ergosterol.

Indication

Itraconazole has a broader spectrum of activity than fluconazole (but not as broad as voriconazole or posaconazole). In particular, it is active against aspergillus, which fluconazole is not. It is also licenced for use in blastomycosis, histoplasmosis and onychomycosis.

Dosing

Itraconazole is available as capsules or as an oral solution. The dose is 200mg once a day, to 400mg in severe infection. There is an intravenous preparation available in the US, but not in the UK. In the UK, if an intravenous preparation is required, then an alternative antifungal drug should be used.

The main problem with the use of itraconazole is its poor absorption, especially when given in capsule form. The oral solution is much better absorbed and should always be used in preference to the capsule. The cyclodextrin contained in the oral solution can cause an osmotic diarrhoea, and if this is a problem, then half the dose can be given as oral solution and half as capsule in order to reduce the amount of cyclodextrin given. Itraconazole capsules should always be taken with food, as this improves absorption. Itraconazole oral solution should be taken an hour before food, or two hours after food (and likewise if a combination of capsules and oral solution are used). Itraconazole should be taken with orange juice or cola, as absorption is also improved by acid. Absorption of itraconazole is impaired when taken with an antacid, H2-blocker or proton pump inhibitor.

In life-threatening situations, some doctors give an oral loading dose of 200mg three times a day for three days, before dropping down to the usual dose. Because itraconazole absorption is unreliable, blood levels should be monitored at least once a week in those patients who are being treated for life-threatening (or potentially life-threatening) fungal infections.

In intravenous dosing, four doses of itraconazole 200mg are given 12 hours apart, before changing the dose to once daily. There is no safety data for giving the intravenous preparation for more than 14 days continuously.

Adverse effects

Itraconazole is a relatively well tolerated drug (although not as well tolerated as fluconazole or voriconazole) and the range of adverse effects it produces is similar to the other azole antifungals.

  • Elevated alanine aminotransferase levels is found in 4% of people taking itraconazole
  • Congestive Heart Failure

The cyclodextrin that is used to make the syrup preparation can cause diarrhoea.

Read more at Wikipedia.org


[List your site here Free!]


Itraconazole Safe For Patients on Diabetes Drugs
From Family Pratice News, 2/15/00 by Heather Lindsay

Itraconazole can safely be used to treat dermatological disorders in diabetic patients who are taking antidiabetic agents.

This was the conclusion drawn by Dr. J. Verspeelt of the Janssen Research Foundation in Beerse, Belgium, and colleagues after a review of the results of clinical trials and postmarketing surveillance reports.

Concerns had been raised because itraconazole, a broad-spectrum triazole antifungal agent, is known to interfere with drugs metabolized by the cytochrome P450 (GYP) 3A4 system, including cisapride and terfenadine.

In 52 clinical trials, only 1 patient had an itraconazole-related adverse event out of 189 patients with diabetes who received itraconazole for systemic infections, vaginal candidiasis, and other conditions (Dermatology 198[4]:382-84, 1999).

Postmarketing surveillance from the past 10 years yielded 15 reports suggestive of hyperglycemia (10 in patients taking insulin, 5 in patients taking an oral antidiabetic agent) and 9 reports suggestive of hypoglycemia (6 in patients taking insulin, 3 in patients taking an oral antidiabetic drug). This was out of an estimated 500,000 patients with diabetes who took itraconazole during that time period.

No interaction between itraconazole and diabetes drugs was observed.

Onychomycosis and dermatomycosis require swift treatment in patients with diabetes due to the risk of complications, even loss of a limb, and patients with diabetes generally respond well to treatment with itraconazole.

Drug-drug interactions with itraconazole are not expected in diabetic patients taking insulin or diabetes drugs not dependent on the cytochrome P450 3A4 system--like tolbutamide, gliclazide, glibenclamide, glipizide, and metformin, Dr. Verspeelt and colleagues said.

COPYRIGHT 2000 International Medical News Group
COPYRIGHT 2001 Gale Group

Return to Itraconazole
Home Contact Resources Exchange Links ebay